Twist Bioscience Corp (TWST) — SEC Filings
Twist Bioscience Corp (TWST) — 33 SEC filings. Latest: 10-K (Nov 17, 2025). Includes 13 SC 13G/A, 7 8-K, 6 10-Q.
View Twist Bioscience Corp on SEC EDGAR
Overview
Twist Bioscience Corp (TWST) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Nov 17, 2025: Twist Bioscience Corporation reported $376.6 million in revenue for fiscal year 2025, driven by its synthetic biology and NGS tools product lines, as well as biopharma services. The healthcare sector contributed $215.1 million, chemicals/materials $93.2 million, academic research $65.9 million, and
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Twist Bioscience Corp is neutral.
Filing Type Overview
Twist Bioscience Corp (TWST) has filed 2 10-K, 7 8-K, 6 10-Q, 2 DEF 14A, 13 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of TWST's 17 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $376.6M |
| Net Income | $N/A |
| EPS | $N/A |
| Debt-to-Equity | N/A |
| Cash Position | $N/A |
| Operating Margin | N/A% |
| Total Assets | $N/A |
| Total Debt | $N/A |
Key Executives
- Dr. Emily M. Leproust
- Dr. William J. Banyai
- Ms. Susan J. J. Bates
- Mr. David L. R. Smith
- Abigail P. Johnson
Industry Context
The synthetic biology market is rapidly expanding, driven by advancements in DNA sequencing, gene editing, and the increasing demand for novel therapeutics, sustainable materials, and improved agricultural products. Companies like Twist Bioscience are at the forefront, industrializing DNA synthesis to accelerate biological engineering and discovery.
Top Tags
institutional-ownership (10) · 10-Q (5) · amendment (5) · biotechnology (4) · passive-investment (4) · Biotechnology (3) · earnings (3) · corporate-governance (3) · financials (3) · Twist Bioscience (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $376.6M | Reported for fiscal year 2025, indicating strong sales across product lines. |
| Healthcare Revenue | $215.1M | Largest revenue contributor in fiscal year 2025, highlighting market focus. |
| Customer Base | 3,800+ | Number of global customers served in fiscal year 2025, showing broad adoption. |
| Chemical Reduction | 99.8% | Estimated reduction in chemicals used per gene compared to plate-based synthesis, demonstrating efficiency. |
| Express Genes Turnaround | 5 days | Rapid delivery time for perfect-quality clonal genes, a key competitive differentiator. |
| Gene Fragment Error Rate | 1:7500 | High accuracy for gene fragments, crucial for research reliability. |
| Oligonucleotides per chip | 1,000,000+ | Capacity of the silicon chip platform, showcasing high throughput. |
| Market Value (Non-affiliates) | $2.32B | As of March 31, 2025, reflecting significant market capitalization. |
| Conformed Period of Report | 2025-06-30 | End date of the reporting period for this 10-Q |
| Filed As Of Date | 2025-08-04 | Date the 10-Q was officially filed with the SEC |
| Subsequent Event Date | 2025-07-31 | Date of an undisclosed subsequent event mentioned in the filing |
| Fiscal Year End | 09-30 | Twist Bioscience Corp's fiscal year end month and day |
| Filing Date | 2024-11-18 | The date the 10-K was officially filed with the SEC. |
| Fiscal Quarter | Q3 2024 | Reporting period for the 10-Q filing |
| Period End Date | 2024-06-30 | The end date of the financial reporting period |
Forward-Looking Statements
- {"claim":"Twist Bioscience Corp's stock price may experience a slight positive reaction due to increased institutional confidence.","entity":"Twist Bioscience Corp","targetDate":"1-3 months","confidence":"medium"}
- {"claim":"Other institutional investors may re-evaluate their positions in Twist Bioscience Corporation following Nikko Asset Management's complete divestment.","entity":"Twist Bioscience Corporation","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"Twist Bioscience Corp's stock price may experience increased stability due to institutional backing.","entity":"Twist Bioscience Corp","targetDate":"Next 6-12 months","confidence":"medium"}
- {"claim":"Other institutional investors might increase their positions in Twist Bioscience, following William Blair's lead.","entity":"Twist Bioscience Corp","targetDate":"Next 3-6 months","confidence":"low"}
- {"claim":"Twist Bioscience's stock price may experience downward pressure due to the reduced institutional ownership.","entity":"Twist Bioscience Corp","targetDate":"Next 3-6 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Twist Bioscience Corp (TWST)?
Twist Bioscience Corp has 33 recent SEC filings from Jan 2024 to Nov 2025, including 13 SC 13G/A, 7 8-K, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TWST filings?
Across 33 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Twist Bioscience Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Twist Bioscience Corp (TWST) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Twist Bioscience Corp?
Key financial highlights from Twist Bioscience Corp's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TWST?
The investment thesis for TWST includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Twist Bioscience Corp?
Key executives identified across Twist Bioscience Corp's filings include Dr. Emily M. Leproust, Dr. William J. Banyai, Ms. Susan J. J. Bates, Mr. David L. R. Smith, Abigail P. Johnson.
What are the main risk factors for Twist Bioscience Corp stock?
Of TWST's 17 assessed filings, 0 were flagged high-risk, 13 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Twist Bioscience Corp?
Recent forward-looking statements from Twist Bioscience Corp include guidance on {"claim":"Twist Bioscience Corp's stock price may experience a slight positive reaction due to increased institutional c and 4 other predictions.